Results of H pylori eradication
| Study . | Bacterial eradication (%)* . | Platelet response (%)† . | Platelet count before eradication, ×109/L‡ . | Platelet count after eradication, ×109/L‡ . | Follow-up duration, mo§ . | No. of relapsed patients . |
|---|---|---|---|---|---|---|
| Gasbarrini et al (1998)2 | 8/11 (73) | NA | 95 ± 39 | 140 ± 34 | 4 | NR |
| Jarque et al (2001)18 | 23/32 (72) | 3/23 (13) | 58 ± 24 | 65 ± 32 | 21 (18–24) | 2 |
| Kohda et al (2002)19 | 19/19 (100) | 12/19 (63) | 67 ± 54 | 120 ± 50 | 14.8 (9–39) | 0 |
| Hino et al (2003)20 | 18/21 (86) | 8/18 (44) | 37 ± 21 | 67 ± 54 | 37.8 | NR |
| Hashino et al (2003)21 | 13/14 (93) | 9/13 (69) | 58 ± 30 | 99 ± 56 | 15 | 1 |
| Ando et al. (2003)22 | 27/29 (93) | 16/27 (59) | 56 ± 24 | 93 ± 49 | 11 (4–15) | 1 |
| Michel et al (2004)23 | 14/15 (93) | 4/14 (29) | 32 ± 15 | 66 ± 98 | 11.5 (3–18) | 1 |
| Takahashi et al (2004)24 | 13/15 (87) | 7/13 (54) | 40 ± 27 | 101 ± 86 | 4 | NR |
| Sato et al (2004)25 | 27/32 (84) | 15/27 (56) | 54 ± 17 | 110 ± 21 | 12 | 0 |
| Ando et al (2004)26 | 15/17 (88) | 10/15 (67) | 49 ± 26 | 168 ± 43 | 24 | 0 |
| Nomura et al (2004)27 | 12/28 (43) | 12/12 (100) | 29 ± 6 | 78 ± 11 | NR | NR |
| Veneri et al (2005)28 | 32/34 (94) | 18/32 (56) | 57 ± 23 | 122 ± 33 | 24.2 (3–62) | 1 |
| Inaba et al (2005)29 | 25/25 (100) | 11/25 (44) | 52 ± 26 | NR | NR | 0 |
| Stasi et al (2005)30 | 52/52 (100) | 16/52 (31) | 42 ± 25 | 129 ± 61 | 25 (7–42) | 6 |
| Fujimura et al (2005)39 | 161/207 (78) | 88/161 (55) | NR | NR | 12 (3–12) | NR |
| Suzuki et al (2005)17 | 22/25 (88) | 6/22 (28) | 55 ± 27 | 114 ± 90 | 6 | NR |
| Suvajdzić et al (2006)31 | 23/30 (77) | 6/23 (26) | 68 ± 33 | 84 ± 45 | 18 (14–32) | 0 |
| Ahn et al (2006)32 | 15/15 (100) | 1/15 (7) | 72 ± 45 | 69 ± 65 | (6–24) | 1 |
| Sayan et al (2006)33 | 18/20 (90) | 11/18 (61) | 39 ± 16 | 100 ± 63 | 11 (4–24) | 0 |
| Asahi et al (2006)34 | 26/26 (100) | 16/26 (61) | 35 ± 13 | 114 ± 61 | >12 | 0 |
| Kodama et al (2007)35 | 44/52 (85) | 27/44 (61) | 40 ± 29 | NR | NR | NR |
| Campuzano-Maya (2007)40 | 26/29 (90) | 21/26 (81) | 57 ± 38 | 198 ± 98 | 12.2 | NR |
| Estrada-Gómez et al (2007)36 | 14/14 (100) | 2/14 (14) | NR | NR | 5 (2–7) | 1 |
| Satake et al (2007)37 | 23/25 (92) | 13/23 (57) | NR | NR | 25.4‖ (6–48) | 0 |
| Emilia et al (2007)38 | 34/38 (89) | 25/34 (74) | 41 ± 24 | 134 ± 96 | 43.5 (18–90) | 1 |
| Study . | Bacterial eradication (%)* . | Platelet response (%)† . | Platelet count before eradication, ×109/L‡ . | Platelet count after eradication, ×109/L‡ . | Follow-up duration, mo§ . | No. of relapsed patients . |
|---|---|---|---|---|---|---|
| Gasbarrini et al (1998)2 | 8/11 (73) | NA | 95 ± 39 | 140 ± 34 | 4 | NR |
| Jarque et al (2001)18 | 23/32 (72) | 3/23 (13) | 58 ± 24 | 65 ± 32 | 21 (18–24) | 2 |
| Kohda et al (2002)19 | 19/19 (100) | 12/19 (63) | 67 ± 54 | 120 ± 50 | 14.8 (9–39) | 0 |
| Hino et al (2003)20 | 18/21 (86) | 8/18 (44) | 37 ± 21 | 67 ± 54 | 37.8 | NR |
| Hashino et al (2003)21 | 13/14 (93) | 9/13 (69) | 58 ± 30 | 99 ± 56 | 15 | 1 |
| Ando et al. (2003)22 | 27/29 (93) | 16/27 (59) | 56 ± 24 | 93 ± 49 | 11 (4–15) | 1 |
| Michel et al (2004)23 | 14/15 (93) | 4/14 (29) | 32 ± 15 | 66 ± 98 | 11.5 (3–18) | 1 |
| Takahashi et al (2004)24 | 13/15 (87) | 7/13 (54) | 40 ± 27 | 101 ± 86 | 4 | NR |
| Sato et al (2004)25 | 27/32 (84) | 15/27 (56) | 54 ± 17 | 110 ± 21 | 12 | 0 |
| Ando et al (2004)26 | 15/17 (88) | 10/15 (67) | 49 ± 26 | 168 ± 43 | 24 | 0 |
| Nomura et al (2004)27 | 12/28 (43) | 12/12 (100) | 29 ± 6 | 78 ± 11 | NR | NR |
| Veneri et al (2005)28 | 32/34 (94) | 18/32 (56) | 57 ± 23 | 122 ± 33 | 24.2 (3–62) | 1 |
| Inaba et al (2005)29 | 25/25 (100) | 11/25 (44) | 52 ± 26 | NR | NR | 0 |
| Stasi et al (2005)30 | 52/52 (100) | 16/52 (31) | 42 ± 25 | 129 ± 61 | 25 (7–42) | 6 |
| Fujimura et al (2005)39 | 161/207 (78) | 88/161 (55) | NR | NR | 12 (3–12) | NR |
| Suzuki et al (2005)17 | 22/25 (88) | 6/22 (28) | 55 ± 27 | 114 ± 90 | 6 | NR |
| Suvajdzić et al (2006)31 | 23/30 (77) | 6/23 (26) | 68 ± 33 | 84 ± 45 | 18 (14–32) | 0 |
| Ahn et al (2006)32 | 15/15 (100) | 1/15 (7) | 72 ± 45 | 69 ± 65 | (6–24) | 1 |
| Sayan et al (2006)33 | 18/20 (90) | 11/18 (61) | 39 ± 16 | 100 ± 63 | 11 (4–24) | 0 |
| Asahi et al (2006)34 | 26/26 (100) | 16/26 (61) | 35 ± 13 | 114 ± 61 | >12 | 0 |
| Kodama et al (2007)35 | 44/52 (85) | 27/44 (61) | 40 ± 29 | NR | NR | NR |
| Campuzano-Maya (2007)40 | 26/29 (90) | 21/26 (81) | 57 ± 38 | 198 ± 98 | 12.2 | NR |
| Estrada-Gómez et al (2007)36 | 14/14 (100) | 2/14 (14) | NR | NR | 5 (2–7) | 1 |
| Satake et al (2007)37 | 23/25 (92) | 13/23 (57) | NR | NR | 25.4‖ (6–48) | 0 |
| Emilia et al (2007)38 | 34/38 (89) | 25/34 (74) | 41 ± 24 | 134 ± 96 | 43.5 (18–90) | 1 |
NR indicates not reported; NA, not assessable.
Results are expressed as the total number of patients with bacterial eradication among the total number of treated patients.
Complete or partial response among patients with successful eradication.
Including noneradicated patients.
Median, with range in parentheses.
Mean value.